ArticleSignal transduction and targeted therapy2023
Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice.
Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Low-dose tamoxifen ameliorates ovariectomy-induced metabolic and immune dysfunction.GeroScience · 2026Article
- NUP85 Mediates Endoplasmic Reticulum Stress through the USP47/ASK1 Signaling Pathway to Regulate the Progression of Liver Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Aspirin Eugenol Ester Ameliorates Fatty Liver Hemorrhagic Syndrome in Laying Hens by Reducing Oxidative Stress and Inflammation.International journal of molecular sciences · 2026Article
- Article
- Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models.Nature reviews. Gastroenterology & hepatology · 2026Review
- Article
- Identification of shared oxidative stress related hub genes in NAFLD and atherosclerosis using bioinformatics and machine learning.Scientific reports · 2026Article
- Targeting STARD10 Alleviates Steatotic Liver Injury by Suppressing YBX1/ACSL1-Mediated Ferroptosis.International journal of biological sciences · 2026Article
- Article
- Natural drugs modulate MAPK: targets and strategies for liver fibrosis treatment.Frontiers in pharmacology · 2026Review
- High-dose tamoxifen impairs the homeostasis of the intestinal stem cell niche by enhancing fatty acid degradation and damaging mitochondria.Apoptosis : an international journal on programmed cell death · 2025Article
- Expression and function of β-site amyloid precursor protein-cleaving enzyme 2 in vascular endothelium.American journal of physiology. Heart and circulatory physiology · 2025Article
- Rhein alleviates hepatic steatosis in NAFLD mice by activating the AMPK/ACC/SREBP1 pathway to enhance lipid metabolism.Molecular medicine (Cambridge, Mass.) · 2025Article
- Morin hydrate protects against cisplatin-induced testicular toxicity by modulating ferroptosis and steroidogenesis genes' expression and upregulating Nrf2/Heme oxygenase-1.Scientific reports · 2025Article
- Identifying shared hub genes in LIRI and MASLD through bioinformatics analysis and machine learning.Scientific reports · 2025Article
- Cardamom extract alleviates tamoxifen-induced liver damage by suppressing inflammation and pyroptosis pathway.Scientific reports · 2025Article
- Hyperuricemia in ob/ob mice relates to hepatocellular pyruvate metabolism/ xanthine oxidase axis.PloS one · 2025Article
- Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD.ImmunoTargets and therapy · 2025Review
- Nano-strategies for Targeting Tumor-Associated Macrophages in Cancer immunotherapy.Journal of Cancer · 2025Review
- Xiaohua Funing decoction ameliorates non-alcoholic fatty liver disease by modulating the gut microbiota and bile acids.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) which is a leading cause of chronic liver diseases lacks effective treatment. Tamoxifen has been proven to be the first-line chemotherapy for several solid tumors in clinics, however, its therapeutic role in NAFLD has never been elucidated before. In vitro experiments, tamoxifen protected hepatocytes against sodium palmitate-induced lipotoxicity. In male and female mice fed with normal diets, continuous tamoxifen administration inhibited lipid accumulation in liver, and improved glucose and insulin intolerance. Short-term tamoxifen administration largely improved hepatic steatosis and insulin resistance, however, the phenotypes manifesting inflammation and fibrosis remained unchanged in abovementioned models. In addition, mRNA expressions of genes related to lipogenesis, inflammation, and fibrosis were downregulated by tamoxifen treatment. Moreover, the therapeutic effect of tamoxifen on NAFLD was not gender or ER dependent, as male and female mice with metabolic disorders shared no difference in response to tamoxifen and ER antagonist (fulvestrant) did not abolish its therapeutic effect as well. Mechanistically, RNA sequence of hepatocytes isolated from fatty liver revealed that JNK/MAPK signaling pathway was inactivated by tamoxifen. Pharmacological JNK activator (anisomycin) partially deprived the therapeutic role of tamoxifen in treating hepatic steatosis, proving tamoxifen improved NAFLD in a JNK/MAPK signaling-dependent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.